CONTEXT: The effect of the female sex steroids, estradiol and progesterone, on muscle protein turnover is unclear. Therefore, it is unknown whether the changes in the hormonal milieu throughout the life span in women contribute to the changes in muscle protein turnover and muscle mass (eg, age associated muscle loss). OBJECTIVE: The objective of this study was to provide a comprehensive evaluation of the effect of sex hormones on muscle protein synthesis and gene expression of growth-regulatory factors [ie, myogenic differentiation 1 (MYOD1), myostatin (MSTN), follistatin (FST), and forkhead box O3 (FOXO3)]. SUBJECTS AND DESIGN: We measured the basal rate of muscle protein synthesis and the expression of muscle growth-regulatory genes in 12 premenopausal women and four groups of postmenopausal women (n=24 total) who were studied before and after treatment withT, estradiol, or progesterone or no intervention (control group). All women were healthy, and pre- and postmenopausal women were carefully matched on body mass, body composition, and insulin sensitivity. RESULTS: The muscle protein fractional synthesis rate was approximately 20% faster, and MYOD1, FST, and FOXO3mRNA expressions were approximately 40%-90% greater (all P<.05) in postmenopausal than premenopausal women. In postmenopausal women, both T and progesterone treatment increased the muscle protein fractional synthesis rate by approximately 50% (both P<.01), whereas it was not affected by estradiol treatment and was unchanged in the control group. Progesterone treatment increased MYOD1 mRNA expression (P<.05) but had no effect on MSTN, FST, and FOXO3 mRNA expression. T and estradiol treatment had no effect on skeletal muscle MYOD1, MSTN, FST, and FOXO3 mRNA expression. CONCLUSION: Muscle protein turnover is faster in older, postmenopausal women compared with younger, premenopausal women, but these age-related differences do not appear to be explained by the age- and menopause-related changes in the plasma sex hormone milieu.
RCT Entities:
CONTEXT: The effect of the female sex steroids, estradiol and progesterone, on muscle protein turnover is unclear. Therefore, it is unknown whether the changes in the hormonal milieu throughout the life span in women contribute to the changes in muscle protein turnover and muscle mass (eg, age associated muscle loss). OBJECTIVE: The objective of this study was to provide a comprehensive evaluation of the effect of sex hormones on muscle protein synthesis and gene expression of growth-regulatory factors [ie, myogenic differentiation 1 (MYOD1), myostatin (MSTN), follistatin (FST), and forkhead box O3 (FOXO3)]. SUBJECTS AND DESIGN: We measured the basal rate of muscle protein synthesis and the expression of muscle growth-regulatory genes in 12 premenopausal women and four groups of postmenopausal women (n=24 total) who were studied before and after treatment with T, estradiol, or progesterone or no intervention (control group). All women were healthy, and pre- and postmenopausal women were carefully matched on body mass, body composition, and insulin sensitivity. RESULTS: The muscle protein fractional synthesis rate was approximately 20% faster, and MYOD1, FST, and FOXO3 mRNA expressions were approximately 40%-90% greater (all P<.05) in postmenopausal than premenopausal women. In postmenopausal women, both T and progesterone treatment increased the muscle protein fractional synthesis rate by approximately 50% (both P<.01), whereas it was not affected by estradiol treatment and was unchanged in the control group. Progesterone treatment increased MYOD1 mRNA expression (P<.05) but had no effect on MSTN, FST, and FOXO3 mRNA expression. T and estradiol treatment had no effect on skeletal muscle MYOD1, MSTN, FST, and FOXO3 mRNA expression. CONCLUSION: Muscle protein turnover is faster in older, postmenopausal women compared with younger, premenopausal women, but these age-related differences do not appear to be explained by the age- and menopause-related changes in the plasma sex hormone milieu.
Authors: Christina Wang; Glenn Cunningham; Adrian Dobs; Ali Iranmanesh; Alvin M Matsumoto; Peter J Snyder; Thomas Weber; Nancy Berman; Laura Hull; Ronald S Swerdloff Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958
Authors: Melinda Sheffield-Moore; Douglas Paddon-Jones; Shanon L Casperson; Charles Gilkison; Elena Volpi; Steven E Wolf; Jie Jiang; Judah I Rosenblatt; Randall J Urban Journal: J Clin Endocrinol Metab Date: 2006-08-08 Impact factor: 5.958
Authors: Xuewen Wang; Gordon I Smith; Bruce W Patterson; Dominic N Reeds; Janine Kampelman; Faidon Magkos; Bettina Mittendorfer Journal: Am J Physiol Endocrinol Metab Date: 2012-01-17 Impact factor: 4.310
Authors: Gordon I Smith; Jun Yoshino; Shannon C Kelly; Dominic N Reeds; Adewole Okunade; Bruce W Patterson; Samuel Klein; Bettina Mittendorfer Journal: Cell Rep Date: 2016-10-11 Impact factor: 9.423
Authors: Gail A Greendale; Barbara Sternfeld; MeiHua Huang; Weijuan Han; Carrie Karvonen-Gutierrez; Kristine Ruppert; Jane A Cauley; Joel S Finkelstein; Sheng-Fang Jiang; Arun S Karlamangla Journal: JCI Insight Date: 2019-03-07
Authors: Christine A Cabelka; Cory W Baumann; Brittany C Collins; Nardina Nash; Gengyun Le; Angus Lindsay; Espen E Spangenburg; Dawn A Lowe Journal: Exp Gerontol Date: 2018-11-08 Impact factor: 4.032